Victor Kotsev, Author at Labiotech.eu

About

Victor Kotsev is a reporter-at-large. He does all things business, technology, and international politics, with a special focus on health and biotech. He has spent most of the 2010s covering the Balkans and the Middle East for the likes of USA Today, Globe and Mail, and Fast Company, primarily out of Istanbul.

Articles by Victor Kotsev

News and Trends 14 Jul 2022

Agomab bags $114 million in thriving regenerative medicine sector

The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This Pfizer-led financing round extension is just the latest sign that the emerging field of regenerative medicine is coming to the fore. Agomab has embarked on an ambitious path to redefine how we understand regenerative medicine […]

July 14, 2022 - 3 minutesmins - By Victor Kotsev

stephanie bewick destiny pharma chief business officer

Expert Advice 2 May 2022

Chief Business Officers: Shedding Light on Biotech’s Dealmakers

In addition to helping patients, biotech companies need to focus on the commercial potential of their work. Stephanie Bewick at Destiny Pharma outlines her experiences of how a Chief Business Officer maximizes their company’s commercial appeal and lands deals in the biotech industry. Stephanie Bewick began her career as an academic researcher before spending more […]

May 2, 2022 - 5 minutesmins - By Victor Kotsev

News and Trends 11 Mar 2022

Microbiome Space in Spotlight as Microbiotica Sets Funding Record

Competition is heating up in the microbiome niche as UK-based Microbiotica raised €60M (£50M) in a Series B round to advance two candidates designed to treat cancer and ulcerative colitis. Microbiotica’s financing sets a record in Europe for microbiome specialist biotechs. The round was co-led by Sweden’s Flerie Invest and China-based Tencent, and was supported […]

March 11, 2022 - 3 minutesmins - By Victor Kotsev

News and Trends 8 Feb 2022

Reforms of EU Clinical Trial Regulations Bring Cautious Optimism

The EU’s clinical trial regulations received a major overhaul at the end of January 2022 to make trials easier to run across EU member states. It may bring some short-term chaos, industry insiders say, but down the road it is likely to pay off. At the start of February, the EU’s new Clinical Trials Regulation […]

February 8, 2022 - 5 minutesmins - By Victor Kotsev

Kees Melief Chief Scientific Officer ISA Pharmaceuticals

Expert Advice 24 Jan 2022

Transitioning from Academia to Chief Scientific Officer in the Biotech Industry

Academics with a drive to turn their research into commercial products often end up in the position of Chief Scientific Officer at a biotech company. Kees Melief shares his own personal experience transitioning from academia to industry. After his retirement as an academic researcher at Leiden University, Cornelis ‘Kees’ Melief founded and became the Chief […]

January 24, 2022 - 5 minutesmins - By Victor Kotsev

News and Trends 25 Nov 2021

Despite New Approvals, Covid-19 Treatments Lag Behind Vaccines

The EU recently added two drugs to its list of approved Covid-19 treatments. Yet with vaccines often in the spotlight, treatment options available to doctors remain few. Earlier this month, the European Commission gave its stamp of approval to two antibody treatments for Covid-19: regdanvimab from the South Korean firm Celltrion Healthcare, and a blend […]

November 25, 2021 - 6 minutesmins - By Victor Kotsev

News and Trends 10 Nov 2021

Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks

German life sciences heavyweight Evotec raised around €376M ($435M) in its US debut on the Nasdaq last week, fueling tentative hopes of renewed investor interest in biotech stocks after a rollercoaster year. The company downsized its initial IPO target of around €500M ($576M) by offering fewer shares than initially planned. This is widely seen as […]

November 10, 2021 - 4 minutesmins - By Victor Kotsev

Expert Advice 1 Nov 2021

“The Board of Directors Should Let the CEO Run the Company”

The relationship between the board and the CEO can be essential to the success of a life sciences company. Drawing from his experience at both sides, Alan Levy shares his advice on how to make that relationship work. Once known as the person who introduced portable defibrillators on the market in the 1990s, Alan Levy […]

November 1, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 26 Oct 2021

Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial

Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established technology that could confer broader immunity to the virus than shots currently on the market. Valneva’s vaccine candidate consists of a killed or ‘inactivated’ version of SARS-CoV-2, the virus responsible for Covid-19. The vaccine was […]

October 26, 2021 - 5 minutesmins - By Victor Kotsev

oxford nanopore technologies genomics sequencing

News and Trends 15 Oct 2021

Third-Generation DNA Sequencing Shines with Oxford Nanopore’s IPO

Oxford Nanopore Technologies, until recently one of very few unicorns in the European biotech industry, had a stellar IPO on the London Stock Exchange late last month. This is ushering in a whole new generation of DNA sequencing, genetics research, and diagnostics. During the first day of the IPO, which bagged the firm over €400M […]

October 15, 2021 - 5 minutesmins - By Victor Kotsev

Switzerland longevity geroscience foundation

News and Trends 11 Oct 2021

Longevity Foundation to Fund Geroscience Research with €860M

The newly-created Longevity Science Foundation aims to extend the human lifespan to more than 120 years by channeling over €860M ($1B) into early-stage geroscience research in the next decade. Experts say that’s a worthy if complex goal. Based in Zug, Switzerland, the Longevity Science Foundation will prioritize four areas of research: personalized medicine, therapeutics, artificial […]

October 11, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 4 Oct 2021

Non-Viral Gene Therapies Get €51M Boost, Though Challenges Remain

Although most gene therapy still relies on non-infectious viral vectors for delivery, a recent venture financing round for the Swiss company Anjarium Biosciences has shone the spotlight on alternative vectors, including lipid nanoparticles and electric pulses. Last month, Anjarium Biosciences raised €51M (CHF55.5M) in a Series A financing round to advance its gene delivery system […]

October 4, 2021 - 5 minutesmins - By Victor Kotsev

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Victor Kotsev

About

Articles by Victor Kotsev

Agomab bags $114 million in thriving regenerative medicine sector

Chief Business Officers: Shedding Light on Biotech’s Dealmakers

Microbiome Space in Spotlight as Microbiotica Sets Funding Record

Reforms of EU Clinical Trial Regulations Bring Cautious Optimism

Transitioning from Academia to Chief Scientific Officer in the Biotech Industry

Despite New Approvals, Covid-19 Treatments Lag Behind Vaccines

Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks

“The Board of Directors Should Let the CEO Run the Company”

Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial

Third-Generation DNA Sequencing Shines with Oxford Nanopore’s IPO

Longevity Foundation to Fund Geroscience Research with €860M

Non-Viral Gene Therapies Get €51M Boost, Though Challenges Remain

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Victor Kotsev

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!